Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

Core Insights - Rein Therapeutics announced the publication of data on its lead drug candidate, LTI-03, demonstrating potential anti-fibrotic properties in lung tissue from patients with idiopathic pulmonary fibrosis (IPF) [1][2] Company Overview - Rein Therapeutics is a biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [5] - The lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling [5] Research Findings - The study published in iScience showed that LTI-03 reduced scarring and protected lung cells in ex vivo lung slices from IPF patients [2][4] - LTI-03 demonstrated the ability to reduce multiple scarring pathways, including TGFβ, VEGF, PDGF, and FGF, while lowering collagen production and inflammatory signals [7] - Unlike the standard-of-care drug nintedanib, LTI-03 achieved these effects without causing cell damage or death, indicating a strong safety profile [7] Market Context - IPF affects approximately 100,000 people in the U.S. and over 70,000 in the U.K., with a median survival of just 3-5 years from diagnosis [4] - The global market for IPF treatments is projected to exceed $11 billion by 2031, highlighting the urgent need for effective therapies [4] Next Steps - Rein has received regulatory approval from the U.K.'s MHRA to initiate the Phase 2 RENEW trial for LTI-03, which will evaluate safety, tolerability, and changes in lung function in up to 120 patients, with initial data expected in 2026 [5]